Researchers at the University of Gothenburg have identified a protein linked to an increased risk of metastasis and recurrence in lung cancer. The findings are presented in a study that paves the way ...
A woman from Somerset is urging others to trust their instincts and to continue pushing for medical appointments after an ...
In the fall of 2022, when I was 42 and living with my wife and three young kids in a small town in northwest Minnesota, a specialist at an unfamiliar hospital approached us with some test results. He ...
Hosted on MSN
The 20-cent supplement from an ancient tree touted as a cure for everything from arthritis to cancer
Scientists are heaping praise onto a little-known ancient tree resin that they say might be able to ease many common ailments — and even help fight cancer. Boswellia serrata is an herbal extract from ...
Breast cancer screening is one of the most important tools doctors have for finding cancer early, when treatment is more likely to succeed. In the United Kingdom, millions of women are invited to have ...
Wellstar West Georgia installs a second Varian TrueBeam system in LaGrange, expanding precise radiation therapy and cutting wait times for cancer patients across the region.
Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.
The UK's first comprehensive evaluation of the use of Artificial Intelligence (AI) in breast cancer screening found that it can increase breast cancer detection by 10.4% and has the potential to ...
A positive story for those going through cancer treatment. The Houston-based non-profit CanCare is stepping in to fill the ...
The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.
André Is an Idiot' chronicles a San Francisco ad guru suffering from terminal cancer. It's the funniest doc about death you'll ever see.
Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results